Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: BMS | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: BMS

Revenues down 4% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BMS

3Q Revenues: $3.9 billion (-4%)

3Q Earnings: $721 million (+4%)

YTD Revenues: $11.6 billion (-3%)

YTD Earnings: $2.0 billion (+8%)

Comments: Excluding the divested Diabetes Alliance, global revenues increased 7%. Baraclude sales were down 14% to $325 million. Reyataz sales were down 10% to $338 million. Sustiva Franchise sales were $357 million, down 8% and Abilify sales were down 21% to $449 million. Eliquis sales grew by $175 million. Yervoy sales were up 47% to $350 million. Sprycel sales were up 22% to $385 million. Orencia sales grew 18% to $444 million. U.S. revenues decreased 3% to $2.0 billion in the quarter. International revenues decreased 4%. R&D expenses increased 10% to $983 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters